AstraZeneca (AZN-lse-151) Financial Ratio Screen
Track AZN-lse-151 screening changes
Get an email when this stock's published screening status or underlying ratios change.
MSCI new-inclusion financial-ratio snapshot
AZN-lse-151 financial screening at a glance
Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Drug Manufacturers - General) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: SEC filing extraction found 53 dimensioned facts; 0 have passed extraction review. No activity conclusion is made. Open the SEC annual filing.
View SEC-extracted business segments
- Oncology Products — 42.6% of filing total · extraction pending
- Cardiovascular And Metabolic Diseases Products — 23.0% of filing total · extraction pending
- Rare Diseases — 16.4% of filing total · extraction pending
- Farxiga — 15.1% of filing total · extraction pending
- Respiratory Products — 14.7% of filing total · extraction pending
- Tagrisso — 13.1% of filing total · extraction pending
- Imfinzi — 10.9% of filing total · extraction pending
- Ultomiris — 8.5% of filing total · extraction pending
- Calquence — 6.3% of filing total · extraction pending
- Lynparza — 5.9% of filing total · extraction pending
- Symbicort — 5.2% of filing total · extraction pending
- Fasenra — 3.6% of filing total · extraction pending
Profile description reviewed: AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Sources to verify: Secondary company profile and classification · Issuer website
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 25.6% / 30% | 5.0% / 30% | 14.0% / 30% | 0.61% / 5% | FINANCIAL SCREEN PASSED* |
| FTSE | 25.6% / 33% | 5.0% / 33% | 14.0% / 50% | 0.61% / 5% | FINANCIAL SCREEN PASSED* |
Financial Highlights
Profitability
| Gross Margin | 81.7% | |
| Operating Margin | 21.6% | |
| Net Margin | 17.4% | |
| Return on Equity (ROE) | 22.8% | |
| Return on Assets (ROA) | 8.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $14.6B |
| Free Cash Flow | $8.7B |
| Total Debt | $29.1B |
| Debt-to-Equity | 61.0 |
| Current Ratio | 0.9 |
| Total Assets | $114.1B |
Price & Trading
| Last Close | GBp 13,830.00 |
| 50-Day MA | GBp 14,392.72 |
| 200-Day MA | GBp 12,789.67 |
| Avg Volume | 2.7M |
| Beta | 0.2 |
|
52-Week Range
GBp 9,573.50
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-03-29 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- Field mapping, formulas and limitations.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About AstraZeneca (AZN-lse-151)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is AstraZeneca (AZN-lse-151) halal to invest in?
The current automated result is Financial screen passed; activity assessment pending. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is AstraZeneca's debt ratio?
AstraZeneca's debt ratio is 25.6% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are AstraZeneca's key financial metrics?
AstraZeneca has a market capitalization of GBp 221800M in its listing currency, trailing P/E ratio of 29.1, and revenue of $58.7B. The company maintains a gross margin of 81.7% and a net margin of 17.4%. Return on equity stands at 22.8%.
How often is the screening data updated?
Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.